Sanofi and Zealand impress with lixisenatide in latest GetGoal study
This article was originally published in Scrip
Executive Summary
Sanofi has reported positive top-line results from another of the nine trials in its Phase III GetGoal programme investigating the once-daily GLP-1 receptor agonist, Lyxumia (lixisenatide), in adults with type 2 diabetes.